Status: Recruiting
Tumor Infiltrating Lymphocyte Therapy for Pediatric High Risk Solid Tumors
Part One of this study will determine the feasibility of creating Tumor-Infiltrating Lymphocyte (TIL) product prospectively from high-risk pediatric solid tumors. Part Two of this study will determine the safety of TIL therapy with lymphodepleting chemotherapy and post-TIL Interleukin-2 in high-risk pediatric solid tumors
Participants needed: 30
Trial details
Phase: Phase 1Age: 1-21Biological sex: AllType: InterventionalSponsor: H. Lee Moffitt Cancer Center and Research InstituteUpdated: Sep 17, 2026Locations: 1
Eligibility criteria
Patients must be ≥1 year to ≤ 21 years of age at time of enrollment to Part One. [+36]
Patients with active systemic infections requiring intravenous antibiotics [+9]